TGF-β in the pathogenesis and prevention of disease: a matter of aneurysmic proportions
Open Access
- 1 February 2010
- journal article
- editorial
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 120 (2), 403-406
- https://doi.org/10.1172/JCI42014
Abstract
TGF-β regulates many aspects of cellular performance relevant to tissue morphogenesis and homeostasis. Postnatal perturbation of TGF-β signaling contributes to the pathogenesis of many disease states, as recently exemplified through the study of Marfan syndrome (MFS), including aortic aneurysm and skeletal muscle myopathy. Heterogeneity in the regulation and consequences of TGF-β signaling, amplified in the context of disease, has engendered confusion and controversy regarding its utility as a therapeutic target. Three studies recently published in the JCI, including one in this issue, underscore the complexity of this subject. Heydemann and colleagues implicate dimorphic variation in latent TGF-β–binding protein 4 (LTBP4), a regulator of TGF-β bioavailability and activation, as a modifier of muscular dystrophy in γ-sarcoglycan–deficient mice. In contrast to experience with ascending aortic aneurysm in MFS, Wang and colleagues show that systemic abrogation of TGF-β signaling worsens (rather than attenuates) Ang II–induced abdominal aortic aneurysm progression in mice. Tieu and colleagues define alterations in the regulation of vascular inflammation in the pathogenesis of Ang II–induced aneurysm and dissection in mice, which may help shed some light on this apparent paradox.This publication has 43 references indexed in Scilit:
- Translational Mini-Review Series on Th17 Cells: Induction of interleukin-17 production by regulatory T cellsClinical and Experimental Immunology, 2009
- The monocyte chemoattractant protein-1/CCR2 loop, inducible by TGF-β, increases podocyte motility and albumin permeabilityAmerican Journal of Physiology-Renal Physiology, 2009
- Transforming Growth Factor-β Promotes Recruitment of Bone Marrow Cells and Bone Marrow-derived Mesenchymal Stem Cells through Stimulation of MCP-1 Production in Vascular Smooth Muscle CellsPublished by Elsevier BV ,2009
- ANG II infusion promotes abdominal aortic aneurysms independent of increased blood pressure in hypercholesterolemic miceAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- The role of endothelial-to-mesenchymal transition in cancer progressionBritish Journal of Cancer, 2008
- Angiotensin II Blockade and Aortic-Root Dilation in Marfan's SyndromeThe New England Journal of Medicine, 2008
- Myofibroblast contraction activates latent TGF-β1 from the extracellular matrixThe Journal of cell biology, 2007
- Rationale and design of a randomized clinical trial of β-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndromeAmerican Heart Journal, 2007
- Angiotensin II type 1 receptor blockade attenuates TGF-β–induced failure of muscle regeneration in multiple myopathic statesNature Medicine, 2007
- Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan SyndromeScience, 2006